LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy
Ex vivo-produced dendritic cells (DCs) constitute the core of active cellular immunotherapy (ACI) for cancer treatment. After many disappointments in clinical trials, the current protocols for their preparation are attempting to boost their therapeutic efficacy by enhancing their functionality towar...
Saved in:
Main Authors: | Dmitry Stakheev (Author), Pavla Taborska (Author), Katerina Kalkusova (Author), Jirina Bartunkova (Author), Daniel Smrz (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antimicrobial Peptide Loss, Except for LL-37, is not Characteristic of Atopic Dermatitis
by: Lilla Szabó, et al.
Published: (2023) -
Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model
by: Oriana Simonetti, et al.
Published: (2021) -
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
by: Kylen E. Ridyard, et al.
Published: (2021) -
Serum Levels of LL-37 and Inflammatory Cytokines in Plaque and Guttate Psoriasis
by: Young Ji Hwang, et al.
Published: (2014) -
Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy
by: Fatai Lu, et al.
Published: (2022)